Veterinary Clinical Trials Market Report 2026

The veterinary clinical trials market size has grown strongly in recent years. It will grow from $4.85 billion in 2025 to $5.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to growth in veterinary pharmaceutical research, increasing pet ownership rates, rising demand for evidence-based veterinary treatments, expansion of academic research programs, improved regulatory frameworks for animal trials.

The veterinary clinical trials market size is expected to see strong growth in the next few years. It will grow to $7.61 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to increasing investments in veterinary drug development, rising adoption of precision medicine for animals, expansion of CRO involvement in veterinary trials, growing focus on chronic and oncology indications, increased use of real-world evidence in animal health. Major trends in the forecast period include increasing adoption of digital trial management platforms, rising use of genomic and biomarker-based studies, growing focus on companion animal clinical research, expansion of multicenter veterinary trials, enhanced emphasis on data integrity and compliance.

The growing number of pet owners is expected to drive the expansion of the veterinary clinical trials market in the coming years. Pet ownership involves keeping and caring for one or more animals as domestic companions. This trend is fueled by factors such as the desire for companionship, the benefits of pet therapy, and increasing awareness of the positive effects pets have on mental and physical well-being. Veterinary clinical trials support pet ownership by improving access to advanced treatments and enhancing overall veterinary care, leading to better health outcomes for animals. For example, in June 2025, data from Petfood Industry, a US-based pet food company, indicated that approximately 68 million dogs were owned by American households, up from 65.1 million in the 2023-2024 survey. As a result, the rising pet ownership trend is contributing to the growth of the veterinary clinical trials market.

Companies in the veterinary clinical trials market are increasingly focused on developing innovative anti-aging drugs aimed at extending pet longevity and improving overall health. Novel anti-aging drugs are medications designed to slow or reverse aging processes, enhancing the vitality and health of senior animals. For instance, in February 2024, Loyal, a US-based veterinary company, initiated a clinical trial for a new anti-aging drug, LOY-002, targeting the extension of healthy lifespan in senior dogs. LOY-002 is intended to improve metabolic health in aging dogs and address age-related changes that can lead to various health issues. This chewable medication, formulated for most older dog breeds except the smallest, is being evaluated in the STAY study, which plans to enroll over 1,000 dogs aged 10 and older across more than 50 veterinary clinics in the United States. The goal of LOY-002 is to enhance metabolic function, potentially delay age-related diseases, and improve overall quality of life in senior dogs.

In September 2024, Boehringer Ingelheim Group, a Germany-based pharmaceutical company, acquired Saiba Animal Health AG for an undisclosed amount. This acquisition strengthens Boehringer Ingelheim’s animal health research and development pipeline, particularly within the rapidly growing pet therapeutics sector, by incorporating Saiba Animal Health’s innovative technology platform. Saiba Animal Health AG, a Switzerland-based biotechnology research company, specializes in developing novel therapeutic medicines for managing chronic diseases in pets, supporting Boehringer Ingelheim’s expansion in advanced pet healthcare solutions.

Major companies operating in the veterinary clinical trials market are Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., Elanco Animal Health Incorporated, Charles River Laboratories International Inc., IDEXX Laboratories Inc., Ceva Santé Animale, Hill's Pet Nutrition Inc., Ethos Veterinary Health LLC, Orion Corporation, Dechra Pharmaceuticals plc, Morris Animal Foundation, Vaxine Pty Ltd, Bioagile Therapeutics Pvt. Ltd., VetStem Inc., VetDC, Vivesto AB, OCRvet, Vetbiolix, Clinvet International, Ondax Scientific S.l., Veterinary Research Management.

North America was the largest region in the veterinary clinical trials market in 2025. The regions covered in the veterinary clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the veterinary clinical trials market by increasing costs of imported laboratory equipment, diagnostic devices, reagents, and data management systems used in trial execution. Research institutions and pharmaceutical companies in North America and Europe are most affected due to dependence on specialized imported tools, while Asia-Pacific faces higher operational costs for trial infrastructure. These tariffs are increasing overall trial expenses and extending study timelines. At the same time, they are supporting local manufacturing of research equipment, regional CRO expansion, and development of domestic trial capabilities.

The veterinary clinical trials market research report is one of a series of new reports that provides veterinary clinical trials market statistics, including veterinary clinical trials industry global market size, regional shares, competitors with a veterinary clinical trials market share, detailed veterinary clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary clinical trials industry. This veterinary clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary clinical trials are systematic research studies carried out to assess the safety, effectiveness, and outcomes of new treatments, drugs, or medical devices intended for animal use. These trials adhere to defined protocols and are designed to evaluate the performance of therapeutic interventions in the prevention, diagnosis, or treatment of animal health conditions.

The primary animal categories involved in veterinary clinical trials include livestock animals, companion animals, and others. Livestock animals are domesticated species raised for agricultural production, such as meat, milk, eggs, wool, and related products, and commonly include cattle, sheep, pigs, goats, and poultry. These animals are treated across a range of indications, including oncology, internal medicine, orthopedics, cardiology, neurology, ophthalmology, dermatology, and others, using interventions such as pharmaceuticals, medical devices, and additional therapies. The main end users of veterinary clinical trials include academic and research institutions, pharmaceutical and biopharmaceutical companies, and other organizations.

The veterinary clinical trials market includes revenues earned by entities by providing services such as study design and protocol development, regulatory compliance and submission, data collection and analysis, and monitoring and quality assurance. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.